- Clinical Experience
- Rheumatology
- Pulmonology
- Ophthalmology
- Nephrology
- Neurology
- Proposed MOA
- Dosing & Duration
- Safety Data
- Support & Resources
-
Flexible dosing regimens allow you to titrate up or down according to your patient’s needs to help achieve treatment goals.1
Recommended dosing from the label1
For IS: 150 units/m2 divided into twice-daily intramuscular injections of 75 units/m2 over a 2‑week period*‡
Calculate the precise dosage and tapering schedule for your IS patients
DM/PM=dermatomyositis/polymyositis; IM=intramuscularly; IS=infantile spasms; MS=multiple sclerosis; PsA=psoriatic arthritis; RA=rheumatoid arthritis; SC=subcutaneously; SLE=systemic lupus erythematosus.
*Acthar Gel is provided as a 5-mL multidose vial containing 80 USP units per mL.
†It may be necessary to taper the dose or increase the injection interval to gradually discontinue treatment.
‡Dosing should then be gradually tapered over a 2‑week period to avoid adrenal insufficiency.
Simply call Acthar Support at 1-877-503-7746
Monday through Friday, 8 AM to 9 PM ET
Saturday, 9 AM to 2 PM ET
This chart does not include all studies available. These studies are subject to various limitations.
§Acthar Gel is provided as a 5-mL multidose vial containing 80 USP units per mL.1
||It may be necessary to taper the dose or increase the injection interval to gradually discontinue treatment.1
¶Ten of the 11 enrolled patients completed the study. One patient dropped out due to heart block unrelated to the study drug and was not included in the efficacy analysis, as she did not complete the minimum 8 weeks of the study drug required for outcome assessment per study protocol.3
#80 units administered twice weekly was the most common dosing regimen information from multiple clinical datasets.5,6
Acthar Gel is indicated for:
Contraindications
Acthar is contraindicated:
Warnings and Precautions
Adverse Reactions
Pregnancy
Please see full Prescribing Information for additional Important Safety Information.
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References:
References: